Abstract
We describe the use of bioactive peptides to drive liposomal drugs on target receptors overexpressed in cancer cells. A detailed description for several targeting liposomes derivatized with different peptides and thus able to target relevant receptors for cancer therapy is reported. Even if the development of peptide-targeted liposomes represents a great advance in the use of liposomal drugs for cancer therapy, many critical issues are still unsolved in the development of these innovative drug delivery systems. Advantages and drawbacks of the peptide-mediated active targeting are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
